Isogenic human SNCA gene dosage induced pluripotent stem cells to model Parkinson's disease


Alpha-synuclein overexpression and aggregation are critical factors in the pathogenesis of Parkinson's disease (PD). Clinical cases with alpha-synuclein (SNCA) multiplications or deletions indicate that gene expression levels are essential for neurodegeneration and neurodevelopment. Here, we developed an isogenic SNCA gene dosage model using CRISPR/Cas9 gene editing to introduce frameshift mutations into exon 2 of the SNCA coding region in human induced pluripotent stem cells (iPSCs) from a patient with an SNCA triplication. We derived and characterized clones with different frameshift mutations. This isogenic SNCA gene dosage panel will address the physiological and detrimental effects of varying alpha-synuclein expression levels. Copyright © 2022. Published by Elsevier B.V.

Authors Zafar F, Nallur Srinivasaraghavan V, Yang Chen M, Alejandra Morato Torres C, Schüle B
Journal Stem cell research
Publication Date 2022 Apr;60:102733
PubMed 35263701
DOI 10.1016/j.scr.2022.102733

Research Projects

Cell Lines